Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

3Q beat

ResMed Inc
3:27pm
April 27, 2025
3Q results were above expectations, with high-single digit revenue growth, expanding operating leverage, and strong cash flow. Sleep and respiratory sales were solid, with resupply and new patient set-ups supporting Americas mask growth, while ROW tracked the market and residential care software sales posted double-digit gains. GPM continues to surprise to the upside, underpinned by manufacturing efficiencies and favourable product mix, while OPM gained on good cost control. Importantly, RMD confirmed its tariff-exempt status, and when taken together with an expanding US manufacturing footprint, new technologies to drive adoption and added benefits from favourable trends in wearables and weight loss drugs, we continue to view the company in a strong competitive position. FY25-27 earnings increase up to 0.7%, with our target price rising to $44.07. Add.

Stellar start to 2025

Newmont Corporation
3:27pm
April 24, 2025
NEM achieved a strong production, cost and cash flow result in the 1Q helped by record high gold prices, which saw it achieve record free cash flow. Net debt reduced by -39% qoq as a result record cash flows and a ~US$1bn debt repayment. NEM has now bought back ~US$755m of its shares since the start of CY25 and expects to continue to do so for the remainder of this year and into CY26. We Maintain our ADD rating with a A$97ps TP (previously A$84ps).

Model update: Q1 traffic and toll revenue, FX rates

Atlas Arteria
3:27pm
April 23, 2025
We update our forecasts to reflect 1Q25 traffic and toll revenue data released by ALX. In addition, we update the AUDEUR and AUDUSD rates used in our modelling, with the decline in the spot AUDEUR particularly beneficial for ALX. Our modelling indicates ALX will have sufficient distributable cashflow and cash reserves to support at least 40 cps of annual DPS until at least the end of the decade. At current prices, this implies a cash yield of 8.1%. 12 month target price lifts 49 cps to $5.09/sh. Total potential 12 month return at current prices is c.11% (or c.4% ex IFM takeover potential). Assuming no corporate activity and given the APRR’s decaying equity value we estimate a 5 year investment IRR at current prices of c.7.0% pa. HOLD retained.

Spring in the step

Imricor Medical Systems
3:27pm
April 23, 2025
IMR has made an exciting start to CY25 which included a major step forward in interventional medicine with the first-in-human ventricular ablation procedure guided by real time MRI. IMR finished 1Q25 in a strong cash position following a A$70m capital raising. Cash receipts remain modest, however subsequent quarters are expected to see growth with the sales teams being strengthened and approvals secured for its 2nd generation Catheter in Europe. Upcoming catalysts include additional sales, clinical trial updates and approvals. We have made no changes to forecasts or valuation. We maintain our Speculative Buy recommendation.

International spotlight

LVMH
3:27pm
April 23, 2025
LVMH Louis Vuitton Moët Hennessy SE is a multinational luxury group conglomerate based in Paris, France. It operates five business segments: Wines and Spirits; Fashion and Leather Goods; Perfume and Cosmetics; Watches & Jewelry; and Selective Retailing. Its 75 brands include Dom Pérignon, Moët & Chandon, Veuve Clicquot, Hennessy, Louis Vuitton, Christian Dior, Givenchy, Acqua di Parma, Tiffany & Co, TAG Heuer, Bulgari, DFS, and Sephora. LVMH operates over 5,600 stores worldwide. LVMH was formed by Bernard Arnault, Alain Chevalier and Henry Racamier in 1987 from the merger of Louis Vuitton and Moët Hennessy. Louis Vuitton itself was founded as a manufacturer of luggage in 1854. Moët Hennessy was formed in 1971 through the merger of the champagne house Moët & Chandon (founded 1743) and the cognac producer Hennessy (founded 1765). Some of LVMH’s more recent acquisitions include Tiffany & Co. in 2020, Rimowa in 2016 and Loro Piana in 2013.

Not now, but soon

Proteomics International Laboratories
3:27pm
April 23, 2025
PIQ has completed a A$4.5m placement to fund the commercial launch across its range of diagnostic tests in Australia and the US as well as upgrading systems and establishing laboratory platforms. The placement coincides with an SPP, aiming to raise a further A$1m. The placement addresses immediate cash concerns, although it appears insufficient to see the company through to meaningful commercial success. We believe that the in-house commercial rollout and reliance on out-of-pocket funding will hinder initial sales and thereby extend the timeframe to achieve meaningful revenues. Notwithstanding our longer-term view that there is substantial value in these tests, we view there is commercial risk, time, expenses, and likely another capital injection to wash through before the sales traction gets interesting. Happy to hold at these levels or add small positions on weakness for risk tolerant investors. Following our changes, our target price is reduced to A$0.43 p/s but we retain our Hold recommendation.

Steadies the ship, builds cash

South32
3:27pm
April 22, 2025
Solid quarter operationally, aside from Cannington’s downgrade, which was not altogether shocking from the aging mine. Net cash of US$252m highlights a strong capital position and solid resilience. Hermosa build and GEMCO restart are key growth levels, with broader portfolio largely in harvest mode – leaving South32 share price sensitive to metal prices. Maintain ADD rating with unchanged A$4.30 target price.

Key name if you are considering a flight-to-quality

BHP Group
3:27pm
April 17, 2025
Strong 3Q25 operational performance was driven by a significant copper beat and resilient WAIO shipments despite cyclone impacts. A major medium-term guidance upgrade for Escondida copper (FY27-FY31) removed a previously anticipated production dip, a significant positive. BMA coal faced headwinds from severe weather and operational issues, leading to a production miss and an increase in FY25 unit cost guidance. Achieved its gender balance target with female participation hitting 40% - another positive competitive differentiator. BHP continues to hold the mantle for best-in-class, with strong earnings quality, return profile and balance sheet. We maintain an ADD rating with A$48.70 TP.

3Q25 traffic, implications of recent bond issuance

Transurban Group
3:27pm
April 17, 2025
We revise our forecasts to reflect 3Q25 traffic data and recent debt issuance in the Eurobond market. FY25F Free Cash is upgraded by 1% and downgraded 1-2% in FY26-27F. HOLD retained, given at current prices we estimate a 12 month potential return of -4% (including 4.7% cash yield) and 5 year investment IRR of <5% pa.

In a superior position to peers

Pilbara Minerals
3:27pm
April 17, 2025
3Q25 was impacted by ramp-up and tie-in activities. FY25 guidance maintained. P1000 ramp-up tracking to plan and improvements expected in June-Q’25. Maintain ADD rating with a A$2.30ps TP (previously A$2.40ps).

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more